At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 156 enrolled
Drug / intervention
Duvelisib +2 moredrug
Likely dose
Duvelisib 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
In Brief
A Phase 2 clinical trial evaluating Duvelisib for Peripheral T-cell Lymphoma. Completed, enrolled 156 participants across 36 sites in 5 countries.
Detailed Summary
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral T-cell Lymphoma
CountriesGermany, Italy, Japan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartFeb 2018
Primary CompletionDec 2023
TodayJul 2026
First PostedDec 13, 2017
Enrollment StartFeb 22, 2018
Primary CompletionDec 22, 2023
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 8.6 years ago
Interventions
Duvelisibdrug
Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
Duvelisibdrug
Duvelisib PO 75 mg BID in 28-day cycles.
Duvelisibdrug
Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase).